Drug
Xl309
Xl309: highest development phase Phase 1, developed by Exelixis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| XL309 NCT05932862 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Xl309 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.